Drugs / MDA-TIL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03610490 | Oct 2018 → Aug 2024 | colorectal adenocarcinoma, ovarian carcinosarcoma, ovarian serous adenocarcinoma, pancreatic ductal adenocarcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDA-TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03610490 ↗ |
| Modality | Cell therapy | “Further characterize the safety profile of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) across multiple tumor types.” NCT03610490 ↗ |
| Route | Intravenous | “Given IV” NCT03610490 ↗ |